This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Jul 1;113(8):e24-e25.

doi: 10.1093/cvr/cvx109.

PCSK9 inhibition and clinical cardiovascular outcomes in patients with atherosclerotic cardiovascular disease

Ulf Landmesser¹

Affiliations

Affiliation

¹ Department of Cardiology, Berlin Institute of Health (BIH), German Center of Cardiovascular Research (DZHK), Charité-Universitätsmedizin Berlin, Berlin, Germany.

PMID: 28863442
DOI: 10.1093/cvr/cvx109

Editorial

PCSK9 inhibition and clinical cardiovascular outcomes in patients with atherosclerotic cardiovascular disease

Ulf Landmesser. Cardiovasc Res. 2017.

. 2017 Jul 1;113(8):e24-e25.

doi: 10.1093/cvr/cvx109.

Author

Ulf Landmesser¹

Affiliation

¹ Department of Cardiology, Berlin Institute of Health (BIH), German Center of Cardiovascular Research (DZHK), Charité-Universitätsmedizin Berlin, Berlin, Germany.

PMID: 28863442
DOI: 10.1093/cvr/cvx109

No abstract available

PubMed Disclaimer

Comment on

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Sabatine MS, et al. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Clinical Trial.

Similar articles

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K, Sharma M, Ferdinand KC. Yadav K, et al. Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L, Robinson JG. Joseph L, et al. Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):19-31. doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1. Prog Cardiovasc Dis. 2015. PMID: 25936907 Review.
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Bergeron N, et al. Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080. Circulation. 2015. PMID: 26503748 Review.
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
Katsiki N, Athyros VG, Mikhailidis DP, Mantzoros C. Katsiki N, et al. Metabolism. 2017 Sep;74:43-46. doi: 10.1016/j.metabol.2017.04.007. Epub 2017 Apr 20. Metabolism. 2017. PMID: 28477848 No abstract available.
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M, Skripuletz T, Napp LC, Berliner D, Akin I, Haghikia A, Akin E, Bauersachs J. Akin M, et al. Cardiovasc Hematol Agents Med Chem. 2017;14(2):94-100. doi: 10.2174/1871525714666160727113740. Cardiovasc Hematol Agents Med Chem. 2017. PMID: 27470008 Review.

See all similar articles

Cited by

The American College of Cardiology 2018; a Starbuckian ODYSSEY and a Black Barbershop.
Daniels MJ. Daniels MJ. Cardiovasc Res. 2018 May 1;114(6):e44-e46. doi: 10.1093/cvr/cvy072. Cardiovasc Res. 2018. PMID: 29648584 Free PMC article. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal